Role of Endothelin in Mediating the Attenuated Renal Hemodynamics in Dahl Salt-Sensitive Hypertension

Hypertension

Volumn 30, Issue 3, 1997, Pages 682-686

  Kassab, Salah ^a   Novak, Jackie ^a   Miller, Todd ^a   Kirchner, Kent ^a   Granger, Joey ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; IODINE 125; IODINE 131; IODOHIPPURIC ACID; IOTALAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM INTAKE; SODIUM URINE LEVEL; URINE FLOW RATE; URINE VOLUME;

ANIMALS; ENDOTHELINS; HEMODYNAMIC PROCESSES; HYPERTENSION; INDANS; KIDNEY; MALE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM, DIETARY;

EID: 0030873672     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.30.3.682     Document Type: Article

References (24)

1. Dahl LK, Heine M. Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res. 1975;36:692-696.
2. Sterzel RB, Luft FC, Gao Y, Shnermann J, Briggs JP, Ganten D, Waldherr R, Schnabel E, Kriz W. Renal disease and the development of hypertension in salt-sensitive Dahl rats. Kidney Int. 1988; 33:1119-1129.
3. Roman RJ. Abnormal renal hemodynamics and pressure-natriuresis relationship in Dahl salt-sensitive rats. Am J Physiol. 1986;251:F57-F65.
4. Uehara Y, Numabe A, Ishimitsu T, Matsuoka H, Yagi S, Sugimoto T. Radical scavengers of indapamide and renal protection in Dahl salt sensitive rats. Hypertens Res. 1992;15:17-26.
5. Uehara Y, Numabe A, Hirawa N, Kawabata Y, Iwai J, Ono H, Matsuoka H, Takabatake Y, Yagi S, Sugimoto T. Antihypertensive effects of cicletanine and renal protection in Dahl salt-sensitive rats. J Hypertens. 1991;9:719-728.
6. Luscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension. 1987;9:157-163.
7. Ohlstein EH, Douglas SA. Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug Res Rev. 1993;29:108-128.
8. Katoh T, Chang H, Uchida S, Okuda T, Kurokawa K. Direct effects of endothelin in the rat kidney. Am J Physiol. 1990;258:F397-F402.
9. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. J Clin Invest. 1989;83:336-342.
10. Bruzzi I, Benigni A. Endothelin is a key modulator of progressive renal injury: experimental data and novel therapeutic strategies. Clin Exp Pharmacol Physiol. 1996;23:349-353.
11. Goligorsky MS, Iijima K, Morgan M, Yanagisawa M, Masaki T, Lin L, Nasjletti A, Kaskel F, Frazer M, Badr KF. Role of endothelin in the development of Dahl hypertension. J Cardiovasc Pharmacol. 1991;17(suppl 7):S484-S491.
12. Uehara Y, Takada S, Hirawa N, Kawabata Y, Ohshima N, Numabe A, Ishimitsu T, Goto A, Yagi S, Omata M. Vasoconstrictors and renal protection induced by B1-selective adrenoceptor antagonist Bisoprolol. J Cardiovasc Pharmacol. 1994;23:897-906.
13. Douglas SA, Gellai M, Ezekiel M, Feuerstein GZ, Elliott JD, Ohlstein EH. Antihypertensive actions of the novel nonpeptide endothelin receptor antagonist SB 209670. Hypertension. 1995;25[pt 2]:818-822.
14. Gellai M, Jugus M, Fletcher T, Nambi P, Ohlstein EH, Elliott JD, Brooks DP. Nonpeptide endothelin receptor antagonists V: prevention and reversal of acute renal failure in the rat by SB 209670. J Pharmacol Exp Ther. 1995;275:200-206.
15. Kato T, Kassab S, Wilkins FC, Kirchner KA, Keiser J, Granger JP. Endothelin antagonists improve renal function in spontaneously hypertensive rats. Hypertension. 1995;25[pt 2]:883-887.
16. Ott CE, Cuche JL, Knox FG. Measurements of renal interstitial fluid pressure with polyethylene matrix capsules. J Appl Physiol. 1975;38:937-941.
17. Pawlowska D, Granger JP, Knox FG. Effects of adenosine infusion into renal interstitium on renal hemodynamics. Am J Physiol. 1987; 252:F678-F682.
18. Schffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension. 1995;25:1135-1143.
19. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 1993;43:354-358.
20. Benigni A, Perico N, Gaspari F, Bellizzi L, Gabanelli M, Remuzzi G. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol. 1991;260:F331-F339.
21. Benigni A, Zoja C, Corna D, Orisio S, Longarretti L, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993;44:440-444.
22. Doucet J, Gonzalez W, Michel JB. Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency. J Cardiovasc Pharmacol. 1996;27:643-651.
23. Gellai M, DeWolf R, Pullen M, Nambi P. Distribution and functional role of renal ET receptor subtypes in normotensive and hypertensive rats. Kidney Int. 1994;46:1287-1294.
24. Pollock DM, Opgenorth TJ. Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation. Am J Physiol. 1993;264(Regulatory Integrative Comp Physiol 33):R222-R226.